Studie - Female Infertility – Pipeline Review, H1 2012

Female Infertility — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Female Infertility - Pipeline Review, H1 2012', provides an overview of the Female Infertility therapeutic pipeline. This report provides information on the therapeutic development for Female Infertility, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Female Infertility. 'Female Infertility - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope

- A snapshot of the global therapeutic scenario for Female Infertility.
- A review of the Female Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Female Infertility pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Female Infertility.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Female Infertility pipeline depth and focus of Female Infertility therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Female Infertility Overview 9

Therapeutics Development 10

An Overview of Pipeline Products for Female Infertility 10

Female Infertility Therapeutics under Development by Companies 12

Female Infertility Therapeutics under Investigation by Universities/Institutes 15

Late Stage Products 18

Comparative Analysis 18

Mid Clinical Stage Products 19

Comparative Analysis 19

Early Clinical Stage Products 20

Comparative Analysis 20

Discovery and Pre-Clinical Stage Products 21

Comparative Analysis 21

Female Infertility Therapeutics — Products under Development by Companies 22

Female Infertility Therapeutics — Products under Investigation by Universities/Institutes 24

Companies Involved in Female Infertility Therapeutics Development 25

Abbott Laboratories 25

Vyteris, Inc. 26

Watson Pharmaceuticals, Inc. 27

Merck & Co., Inc. 28

Euroscreen S.A. 29

Takeda Pharmaceutical Company Limited 30

ASKA Pharmaceutical Co., Ltd 31

Astellas Pharma Inc. 32

Dong-A Pharmaceutical Co., Ltd. 33

Kissei Pharmaceutical Co., Ltd. 34

Teva Pharmaceutical Industries Limited 35

Zydus Cadila Healthcare Limited 36

Pantec Biosolutions AG 37

Merck KGaA 38

Access Pharmaceuticals, Inc. 39

Addex Pharmaceuticals 40

AEterna Zentaris Inc. 41

Soligenix, Inc. 42

Repros Therapeutics Inc. 43

Protalix BioTherapeutics, Inc. 44

Glycotope GmbH 45

Peptron, Inc. 46

Meditrina Pharmaceuticals, Inc. 47

PregLem SA 48

Ferring Pharmaceuticals, Inc. 49

Isifer AB 50

Female Infertility — Therapeutics Assessment 51

Assessment by Monotherapy Products 51

Assessment by Combination Products 52

Assessment by Route of Administration 53

Assessment by Molecule Type 55

Drug Profiles 57

AEZS-115 - Drug Profile 57

TAK-385 - Drug Profile 58

Anastrozole - Drug Profile 59

Elagolix - Drug Profile 61

ADX68692 - Drug Profile 62

GnRH Antagonists - Drug Profile 63

GnRH Patch - Drug Profile 64

Proellex - Drug Profile 65

Recombinant Hormones For Ovulation Induction - Drug Profile 67

LPM Leuprolide - Drug Profile 68

PRX-111 - Drug Profile 70

Fertility Hormone - Drug Profile 71

Drugs For Prostate Cancer & Endometriosis - Drug Profile 72

JR-041 - Drug Profile 73

JR-041 - Drug Profile 74

PGL1001 - Drug Profile 75

PGL2001 - Drug Profile 76

PGL3001 - Drug Profile 77

ESN-364 - Drug Profile 78

OCP - Drug Profile 79

Elonva - Drug Profile 80

DA-3803 - Drug Profile 82

Metformin - Drug Profile 83

Raloxifene - Drug Profile 85

Letrozole - Drug Profile 87

Human Chorionic Gonadotropin - Drug Profile 88

Clomiphene Citrate - Drug Profile 89

Human Chorionic Gonadotropin + Clomiphene Citrate - Drug Profile 90

Leuprolide Acetate - Drug Profile 92

Microdose GnRh Agonist - Drug Profile 94

Metformin - Drug Profile 95

Metformin - Drug Profile 96

MPI-676 - Drug Profile 97

Metformin - Drug Profile 99

Aldactone - Drug Profile 100

Progesterone - Drug Profile 101

Synthetic Gonadotropin Releasing Hormone - Drug Profile 103

XM17 - Drug Profile 104

D-chiro-inositol - Drug Profile 105

Simvastatin - Drug Profile 106

Dexamethasone + Recombinant hCG - Drug Profile 107

GnRH agonist - Drug Profile 109

KLH-2109 - Drug Profile 110

Femara - Drug Profile 111

Neupogen - Drug Profile 112

Recombinant Follicle Stimulating Hormone - Drug Profile 114

Metformin + Clomiphene - Drug Profile 115

Tamoxifen + Clomiphene - Drug Profile 116

Prod 5 - Drug Profile 117

Flutamide + Metformin - Drug Profile 118

Heparin - Drug Profile 119

Clomiphene Citrate + Dexamethasone - Drug Profile 120

Medroxyprogesterone - Drug Profile 121

Metformin - Drug Profile 122

Aspirin - Drug Profile 123

Oral Infertility Drugs - Drug Profile 124

DR-2011 - Drug Profile 125

Afolia - Drug Profile 126

ASP1707 - Drug Profile 127

Neupogen - Drug Profile 128

Isifera - Drug Profile 129

Endole - Drug Profile 130

FSH-GEX - Drug Profile 131

AKP-501 - Drug Profile 133

IVF001 - Drug Profile 134

IVF002 - Drug Profile 135

Prod 6 - Drug Profile 136

Female Infertility Therapeutics — Drug Profile Updates 137

Female Infertility Therapeutics — Discontinued Products 143

Female Infertility Therapeutics - Dormant Products 144

Female Infertility — Product Development Milestones 146

Featured News & Press Releases 146

Appendix 153

Methodology 153

Coverage 153

Secondary Research 153

Primary Research 153

Expert Panel Validation 154

Contact Us 154

Disclaimer 154





List of Tables

Number of Products Under Development for Female Infertility, H1 2012 14

Products under Development for Female Infertility — Comparative Analysis, H1 2012 15

Number of Products under Development by Companies, H1 2012 17

Number of Products under Development by Companies, H1 2012 (Contd..1) 18

Number of Products under Investigation by Universities/Institutes, H1 2012 20

Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 21

Comparative Analysis by Late Stage Development, H1 2012 22

Comparative Analysis by Mid Clinical Stage Development, H1 2012 23

Comparative Analysis by Early Clinical Stage Development, H1 2012 24

Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 25

Products under Development by Companies, H1 2012 26

Products under Investigation by Universities/Institutes, H1 2012 28

Abbott Laboratories, H1 2012 29

Vyteris, Inc., H1 2012 30

Watson Pharmaceuticals, Inc., H1 2012 31

Merck & Co., Inc., H1 2012 32

Euroscreen S.A., H1 2012 33

Takeda Pharmaceutical Company Limited, H1 2012 34

ASKA Pharmaceutical Co., Ltd, H1 2012 35

Astellas Pharma Inc., H1 2012 36

Dong-A Pharmaceutical Co., Ltd., H1 2012 37

Kissei Pharmaceutical Co., Ltd., H1 2012 38

Teva Pharmaceutical Industries Limited, H1 2012 39

Zydus Cadila Healthcare Limited, H1 2012 40

Pantec Biosolutions AG, H1 2012 41

Merck KGaA, H1 2012 42

Access Pharmaceuticals, Inc., H1 2012 43

Addex Pharmaceuticals, H1 2012 44

AEterna Zentaris Inc., H1 2012 45

Soligenix, Inc., H1 2012 46

Repros Therapeutics Inc., H1 2012 47

Protalix BioTherapeutics, Inc., H1 2012 48

Glycotope GmbH, H1 2012 49

Peptron, Inc., H1 2012 50

Meditrina Pharmaceuticals, Inc., H1 2012 51

PregLem SA, H1 2012 52

Ferring Pharmaceuticals, Inc., H1 2012 53

Isifer AB, H1 2012 54

Assessment by Monotherapy Products, H1 2012 55

Assessment by Combination Products, H1 2012 56

Assessment by Stage and Route of Administration, H1 2012 58

Assessment by Stage and Molecule Type, H1 2012 60

Female Infertility Therapeutics — Drug Profile Updates 141

Female Infertility Therapeutics — Discontinued Products 147

Female Infertility Therapeutics — Dormant Products 148





List of Figures

Number of Products under Development for Female Infertility, H1 2012 14

Products under Development for Female Infertility — Comparative Analysis, H1 2012 15

Products under Development by Companies, H1 2012 16

Products under Investigation by Universities/Institutes, H1 2012 19

Late Stage Products, H1 2012 22

Mid Clinical Stage Products, H1 2012 23

Early Clinical Stage Products, H1 2012 24

Discovery and Pre-Clinical Stage Products, H1 2012 25

Assessment by Monotherapy Products, H1 2012 55

Assessment by Combination Products, H1 2012 56

Assessment by Route of Administration, H1 2012 57

Assessment by Stage and Route of Administration, H1 2012 58

Assessment by Molecule Type, H1 2012 59

Assessment by Stage and Molecule Type, H1 2012 60

• Female Hypoactive Sexual Desire Disorder – Pipeline Review, H1 2013
• Cervical Dysplasia – Pipeline Review, H1 2013
• EpiCast Report: Postmenopausal Vaginal Atrophy - Epidemiology Forecast to 2022
• Female Sexual Dysfunction – Pipeline Review, H1 2013
• Menopausal Disorders – Pipeline Review, H1 2013
• Menopausal Hot Flashes – Pipeline Review, H1 2013
• Uterine Fibroids – Pipeline Review, H1 2013
• Vaginal Atrophy (Atrophic Vaginitis) – Pipeline Review, H1 2013
• Contraceptives – Pipeline Review, H1 2013
• Dysmenorrhea – Pipeline Review, H1 2013
• Endometriosis – Pipeline Review, H1 2013
• Women Infertility – Pipeline Review, H1 2013
• Premature Labor (Tocolysis) – Pipeline Review, H2 2012
• Vasomotor Symptoms of Menopause – Pipeline Review, H2 2012
• Contraceptives Market to 2018 - Safety Concerns Plague Drospirenone-containing Birth Control Pills and Long-term Use of Estrogen
• Premature Ovarian Failure – Pipeline Review, H2 2012
• Premenstrual Syndrome – Pipeline Review, H2 2012
• Women’s Health Therapeutics Market to 2018 - Unmet Need for Safe and Effective Treatments due to Unfavorable Risk/Benefit Profile Associated with Hormone Replacement Therapy
• Endometriosis Global Clinical Trials Review, H2, 2012
• Primary Dysmenorrhea – Pipeline Review, H2 2012